Inhalable Drugs for the Treatment of Chronic Respiratory Diseases
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Physical Pharmacy and Formulation".
Deadline for manuscript submissions: 31 October 2024 | Viewed by 1198
Special Issue Editors
Interests: nanomedicine; drug formulation; pharmacy and pharmaceutical science
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Chronic Respiratory Diseases (CRDs) impose a severe burden on patients and society, and have an increasing rate of mortality and morbidity. Common types of these diseases include asthma, chronic obstructive pulmonary disorder (COPD), cystic fibrosis, lung cancer, and sleep apnea. At present, inhalation therapy is receiving a lot of attention from scientists and researchers. Pulmonary drug delivery is an important method for the administration of treatment and the prevention of diseases of the respiratory tract (nasal and pulmonary regions). It also enables the non-invasive delivery of drugs to the central nervous system (CNS). Pulmonary drug delivery has recently gained significance in the therapeutic field due to its many advantages, such as pain-free administration, targeted drug delivery with minimum systemic exposure, the rapid onset of action, and relatively high local concentrations in the lungs.
Attention is also warranted to various pharmaceutical processes such as milling, mixing, spray drying, amorphisation, micronisation, crystallisation, relaxation, dissolution, coating, and storage. These innovating approaches can be used to develop various conventional and controlled release solid dosage forms, such as powders for respiratory delivery and tablets and capsules for oral delivery.
Prof. Dr. Shyamal Das
Dr. Prakash Khadka
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- inhalable formulations
- high-dose formulations
- aerosolization
- pulmonary delivery
- inhalable nanovaccines
- chronic respiratory diseases
